We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Multitiered Molecular Control Mechanism Regulates T-cell Genetic Switch

By LabMedica International staff writers
Posted on 27 Jul 2016
Three distinct molecular processes act in a stage-specific manner to provide a multitiered system for regulating the T-cell developmental gene BCL11B (B-cell CLL/Lymphoma 11B).

During T-cell development, multipotent progenitors commit to the T-cell lineage by turning on the BCL11B gene, which encodes a transcription factor. More...
To identify the factors responsible for controlling the commitment mechanism, investigators at the California Institute of Technology (Pasadena, USA) followed developing T-cells at the single-cell level using mice genetically engineered to express a fluorescent protein in addition to their own Bcl11b protein. This caused the mouse cells to glow under the fluorescent microscope when the BCL11B gene was activated.

Results published in the July 4, 2016, online edition of the journal Nature Immunology revealed that a group of four protein transcription factors cooperated in a series of multi-tiered steps to regulate the T-cell genetic switch.

Initially, the proteins HNF1 homeobox A (HNF1A; also known as TCF1) and GATA binding protein 3 (GATA3) performed an early locus "poising" function, which paved the way for the activation step. Next, Notch protein signaling activated BCL11B. The fourth protein, Runt-related transcription factor 1 (Runx1) controlled the amplitude of the signal.

"We identify the contributions of four regulators of BCL11B, which are all needed for its activation but carry out surprisingly different functions in enabling the gene to be turned on," said senior author Dr. Ellen Rothenberg, professor of biology at the California Institute of Technology. "It is interesting - the gene still needs the full quorum of transcription factors, but we now find that it also needs them to work in the right order. This makes the gene respond not only to the cell's current state, but also to the cell's recent developmental history."

Related Links:
California Institute of Technology



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.